A novel mechanism for HIV1-mediated bystander CD4+ T-cell death: neighboring dying cells drive the capacity of HIV1 to kill noncycling primary CD4+ T cells.
CD4+ T-cell death is a crucial feature of AIDS pathogenesis, but the mechanisms involved remain unclear. Here, we present in vitro findings that identify a novel process of HIV1 mediated killing of bystander CD4+ T cells, which does not require productive infection of these cells but depends on the presence of neighboring dying cells. X4-tropic HIV1 strains, which use CD4 and CXCR4 as receptors for cell entry, caused death of unstimulated noncycling primary CD4+ T cells only if the viruses were produced by dying, productively infected T cells, but not by living, chronically infected T cells or by living HIV1-transfected HeLa cells. Inducing cell death in HIV1-transfected HeLa cells was sufficient to obtain viruses that caused CD4+ T-cell death. The addition of supernatants from dying control cells, including primary T cells, allowed viruses produced by living HIV1-transfected cells to cause CD4+ T-cell death. CD4+ T-cell killing required HIV1 fusion and/or entry into these cells, but neither HIV1 envelope-mediated CD4 or CXCR4 signaling nor the presence of the HIV1 Nef protein in the viral particles. Supernatants from dying control cells contained CD95 ligand (CD95L), and antibody-mediated neutralization of CD95L prevented these supernatants from complementing HIV1 in inducing CD4+ T-cell death. Our in vitro findings suggest that the very extent of cell death induced in vivo during HIV1 infection by either virus cytopathic effects or immune activation may by itself provide an amplification loop in AIDS pathogenesis. More generally, they provide a paradigm for pathogen-mediated killing processes in which the extent of cell death occurring in the microenvironment might drive the capacity of the pathogen to induce further cell death.
Lelièvre
J D
JD
EMI-U 9922 INSERM/Université Paris 7, IFR02, AP-HP, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France. lelievre@im3.inserm.fr
Mammano
F
F
Arnoult
D
D
Petit
F
F
Grodet
A
A
Estaquier
J
J
Ameisen
J C
JC
D000163:Acquired Immunodeficiency Syndrome / Q000503:physiopathology; D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D002453:Cell Cycle; D016923:Cell Death; D002633:Chemotaxis; D053222:Fas Ligand Protein; D015686:Gene Products, env / Q000378:metabolism; D015693:Gene Products, nef / Q000378:metabolism; D015497:HIV-1 / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D019169:Jurkat Cells; D008562:Membrane Glycoproteins / Q000378:metabolism; D008957:Models, Genetic; D019718:Receptors, CXCR4 / Q000378:metabolism; D013601:T-Lymphocytes / Q000473:pathology / Q000821:virology*; D013696:Temperature; D013997:Time Factors; D014162:Transfection; D014466:Ultraviolet Rays; D054311:nef Gene Products, Human Immunodeficiency Virus
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D015686:Gene Products, env; D015693:Gene Products, nef; D008562:Membrane Glycoproteins; D019718:Receptors, CXCR4; D054311:nef Gene Products, Human Immunodeficiency Virus